Efficacy of percutaneous transhepatic cholangiodrainage (PTCD) in patients with unresectable pancreatic cancer

Tumor Biology

Volumn 35, Issue 3, 2014, Pages 2753-2757

  Wu, Jie ^a   Song, Lei ^a   Zhang, Yang ^a   Zhao, Dan Yi ^a   Guo, Bing ^a   Liu, Jing ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

CA199; Chemoradiotherapy; Pancreatic; PTCD; Unresectable

Indexed keywords

ADULT; AGED; ARTICLE; BILIARY STENT; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CHEMORADIOTHERAPY; CLINICAL ARTICLE; FEMALE; HUMAN; INOPERABLE CANCER; MALE; METAL STENT; OBSTRUCTIVE JAUNDICE; OVERALL SURVIVAL; PANCREAS CANCER; PERCUTANEOUS TRANSHEPATIC DRAINAGE; PRIORITY JOURNAL; RADIOGRAPHY DEVICE; SURVIVAL TIME; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BILE; COMBINED MODALITY THERAPY; DRAINAGE; FEMALE; HUMANS; JAUNDICE, OBSTRUCTIVE; MALE; MIDDLE AGED; PALLIATIVE CARE; PANCREATIC NEOPLASMS; RADIOTHERAPY;

EID: 84898912043     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1363-1     Document Type: Article

References (19)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-917.
2. Bosetti C, Bertuccio P, Negri E, La Vecchia C, Zeegers MP, Boffetta P. Pancreatic cancer: overview of descriptive epidemiology. Mol Carcinog. 2012;51:3-13.
3. Sharma C, Eltawil KM, Renfrew PD, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol. 2011;17:867-97.
4. Porta M, Fabregat X, Malats N, et al. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol. 2005;7:189-97.
5. Sohn TA, Lillemoe KD, Cameron JL, Huang JJ, Pitt HA, Yeo CJ. Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s. J Am Coll Surg. 1999;188:658-66.
6. Baron TH. Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract. N Engl J Med. 2001;344:1681-7.
7. Tsuyuguchi T, Takada T, Miyazaki M, et al. Stenting and interventional radiology for obstructive jaundice in patients with unresectable biliary tract carcinomas. J Hepatobiliary Pancreat Surg. 2008;15:69-73.
8. Carter DC. Cancer of the pancreas. Gut. 1990;31:494-6.
9. Kloek JJ, van der Gaag NA, Aziz Y, et al. Endoscopic and percutaneous preoperative biliary drainage in patients with suspected hilar cholangiocarcinoma. J Gastrointest Surg. 2010;14:119-25.
10. Kawakami H, Kuwatani M, Onodera M, et al. Endoscopic nasobiliary drainage is the most suitable preoperative biliary drainage method in the management of patients with hilar cholangiocarcinoma. J Gastroenterol. 2011;46:242-8.
11. Yamagishi Y, Higuchi H, Izumiya M, et al. Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma. J Gastroenterol. 2010;45:1146-54.
12. Soderlund C, Linder S. Covered metal versus plastic stents for malignant common bile duct stenosis: a prospective, randomized, controlled trial. Gastrointest Endosc. 2006;63:986-95.
13. Moss AC, Morris E, Mac Mathuna P. Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database Syst Rev. 2006:CD004200.
14. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer. 1981;48:1705-10.
15. Safi F, Schlosser W, Kolb G, Beger HG. Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms. J Gastrointest Surg. 1997;1:106-12.
16. Kondo N, Murakami Y, Uemura K, et al. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol. 2010;17:2321-9.
17. Lundin J, Roberts PJ, Kuusela P, Haglund C. The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer. 1994;69:515-9.
18. Micke O, Bruns F, Schafer U, Kurowski R, Horst E, Willich N. CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. Anticancer Res. 2003;23:835-40.
19. Bilimoria KY, Bentrem DJ, Ko CY, et al. Validation of the 6th edition AJCC pancreatic cancer staging system: report from the National Cancer Database. Cancer. 2007;110:738-44.